GNW-Adhoc: New Novotech report on metastatic breast cancer identifies 1,000 clinical trials worldwide since 2018

^BOSTON, Dec. November 31, 2023 (GLOBE NEWSWIRE) — Novotech, (https://novotech-

cro.com/reports/gall-bladder-cancer-global-clinical-trial-

landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT

&utm_term=DOWNLOAD-REPORT&utm_content=GBC) the leading Asian-

Pacific-focused biotech CRO with global execution capabilities

today has the latest report on the global clinical trials landscape

Published in 2023 on the topic of metastatic breast cancer.

Novotech’s team of research analysts provides these expert reports on a monthly basis

available completely free of charge. These reports provide up-to-date insights into the

global activity of clinical trials and show in which regions the

highest study volumes have been recorded and what factors are behind them

Trends stand. They address the hurdles that biotech companies face

are confronted with certain therapeutic areas and discuss future ones

Therapy paths and investment trends.

The report Metastatic Breast Cancer – Global Clinical Trial Landscape 2023

shows that there have been over 1,000 clinical trials worldwide since 2018. Besides that

The report states:?Of the 2.3 million breast cancer cases worldwide

0.67 million identified as metastatic breast cancer, with 45% on

Asia, 35% in Western regions and 20% in other regions.”

Download the report here (https://novotech-

cro.com/reports/metastatic-breast-cancer-global-clinical-trial-landscape-

2023?utm_source=MBC+PR&utm_medium=MBC+PR&utm_campaign=MBC+PR)

The report found that?significant differences in mortality depending on

Race and region exist, with higher rates among African Americans, Asians and

Pacific Islanders, while Caucasians have comparatively lower rates

exhibit”.

Metastatic breast cancer, also known as stage IV breast cancer, occurs

occurs when cancer cells spread from the breast to other parts of the body.

Despite advances in early detection and treatment, 20-30% develop

of people initially diagnosed with breast cancer

metastatic breast cancer, which has a 5-year survival rate of 30%

represents a challenge.

The report analyzed global trial data and found:

* The Asia Pacific (APAC) region accounts for over 35% of these

Studies lead, led by mainland China, South Korea and Australia.

* The United States and Europe together accounted for more than half of the

Studies on metastatic breast cancer, with Spain and France

played a key role in these regions.

* The Rest of the World (ROW) accounted for approximately 10% of global studies

metastatic breast cancer.

* The APAC region in particular performed well in recruiting studies

efficient and pointed compared to Europe and the United States

shorter lead times and faster recruitment rates.

The report examined current and future treatment options and

noted that doctors usually treat metastatic breast cancer

systemic medications such as chemotherapy, hormone therapy, targeted therapies

and use immunotherapy.

He also emphasized that the approval of Enhertu for HER2-poor breast cancer in the

Year 2022 represents a milestone for a subgroup of patients

There is hope and the strategy of personalized medicine for more precise and

more effective therapies for metastatic breast cancer.

Novotech employs more than 3,000 people in 25 countries

34 branches, including in the USA, Greater China, South Korea,

Australia, New Zealand and Europe.

The CRO offers biotechnology companies a unique and unparalleled experience

Offering early to late phase contract research services

the USA and Europe, with a focus on the Asia-Pacific region

is where the company has a good reputation in terms of implementation

high-quality accelerated clinical trials. The commitment of the

Company for collaboration is reflected in the 50 Leading Sites

Partnership agreements it has signed in the last three years.

About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-

cancer-global-clinical-trial-

landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT

&utm_term=DOWNLOAD REPORT&utm_content=GBC)

Founded in 1997, Novotech is a global clinical

Full-service contract research organization (CRO) focused on

Collaboration with biotech companies focused on development

of advanced and novel therapeutics at every stage.

Recognized for its industry-leading contributions, Novotech has numerous

Received prestigious awards including the CRO Leadership Award

2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and

since 2006 the Asia-Pacific Contract Research Organization Company of the Year

Award.

The company offers a full range of services including

Laboratories, Phase I facilities, drug development consulting and

regulatory expertise, and has experience with over 5,000 clinical

Projects, including phase I to IV clinical trials and

Bioequivalence studies. With a presence in 34 locations and a dedicated

With a team of more than 3,000 professionals worldwide, Novotech is a trusted one

strategic end-to-end partner of choice.

For more information or to speak to an expert team member,

visit www.Novotech-CRO.com (http://www.novotech-cro.com/)

A photo accompanying this announcement is available

at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f517434-

9cee-438f-803b-7cb4db080bb3

°

ttn-28